Drug – bio-affecting and body treating compositions – Extract – body fluid – or cellular material of undetermined... – Derived from mollusk
Patent
1997-03-26
1999-01-05
Sayala, Chhaya D.
Drug, bio-affecting and body treating compositions
Extract, body fluid, or cellular material of undetermined...
Derived from mollusk
4241851, 530395, 514 8, A61K 3556
Patent
active
058559191
ABSTRACT:
The present intention is directed to a stabilized keyhole limpet hemocyanin (KLH) composition in which (i) its intact non-degraded subunit is approximately 400,000 in molecular weight based on SDS-PAGE analysis; and (ii) are contained at least about 50% didecameric or higher KLH multimers, based on sedimentation-equilibrium and/or sedimentation-velocity ultracentrifugation analyses. The KLH composition is stabilized at 4.degree. C. by dissolving and storing it in an isotonic buffer preferably containing calcium and magnesium. It is critical that the KLH not have been frozen or lyophilized during its preparation or storage. The KLH composition demonstrates enhanced immunogenic activity, particularly enhanced anti-tumor activity, which is reduced if the KLH is frozen or lyophilized. The KLH composition of the present invention exhibits enhanced anti-tumor activity in a murine bladder tumor model and thereby represents a new and useful anti-tumor immunotherapeutic agent.
REFERENCES:
Senozan, N.M. et al., Hemocyanin of the giant keyhole limpet, Megathura crenulate, in: "Invertebrate Oxygen-Binding Proteins", J. Lamy et al., eds., Marcel Dekker, Inc., N.Y., pp. 703-717 (1981).
Herscowitz, H.B. et al., Immunochemical and immunogenic properties of a purified keyhole limpet haemocyanin, Immunology 22:51-61 (1972).
Curtis, J.e. et al., The human secondary immune response to keyhole limpet haemocyanin, Clin. Exp. Immunol. 10:171-177 (1972).
Curtis, J.E. et al., The human primary immune response to keyhole limpet haemocyanin: Interrelationships of delayed hypersensitivity, antibody response and in vitro blast transformation, Clin. Exp. Immunol. 6:473-491 (1970).
Herskovits, T.T. et al., Subunit structure and higher order assembly of the hemocyanins of the melongenidae family: Melongena corona (Gmelin), Busycon canaliculatum (Linne), B. carica (Gmein), B. contrarium (Conrad), and B.
Garvey, J.S., et al., High-molecular-weight hemocyanin. In: "Methods in Immunology", Addison-Wesley Publ. Co., pp. 135-139 (1977).
Herskovits, T.T., Recent aspects of the subunit organization and dissociation of hemocyanins. Comp. Biochem. Physiol. 91B:597-611 (1988).
Herskovits, T.T. et al., Higher order assemblies of molluscan hemocyanins.
Savel-Niemann, A. et al., Keyhole limpet hemocyanin: On the structure of a widely used immunologic tool. In: "Invertebrate Dioxygen Carriers", G. Preaux et al., eds., Leuven University Press, Leuven, pp. 351-356 (1990).
Markl, J. et al., The role of two distinct subunit types in the architecture of keyhole limpet hemocyanin (KLH). Naturwiss. 78:512-514 (1991).
Van Holde, K.E. et al., The Hemocyanins. In: "Subunits in Biological Systems", S.N. Timasheff et al., eds., Marcel Dekker, N.Y., pp. 1-53 (1971).
Ellerton, H.D. et al., Hemocyanin--A current perspective. Prog.Biophys.Mol.Biol. 41:143-248 (1983).
Silverman, D.T. et al., Epidemiology of Bladder Cancer. In: "Hematology/Oncology Clinics of North America", P.W. Kantoff et al., eds., W.B. Saunders Co., Philadelphia, p. 1 (1992).
Itoku, K.A. et al., Superficial Bladder Cancer. In: "Hematology/Oncology Clinics of North America", P.W. Kantoff et al., eds., W.B. Saunders Co., Philadelphia, pp. 99-116 (1992).
Morales, A. et al., Intracavitary bacillus Calmette-Guerin in the treatment of superficial bladder tumors. J. Urol. 116:180-183 (1976).
Morales, A. et al., Immunotherapy for superficial bladder cancer. A developmental and clinical overview. Urol. Clin. Nor. Am. 19:549-556 (1992).
Lamm, D.L., Optimal BCG treatment of superficial bladder cancer as defined by American trials. Eur. Urol. 21 Suppl. 2:12-16 (1992).
Olsson, C.A. et al., Immunologic reduction of bladder cancer recurrence rate. J. Urol. 111:173-176 (1974).
Jurincic, C.D. et al., Immunotherapy in bladder cancer with keyhole-limpet hemocyanin: a randomized study. J. Urol. 139:723-726 (1988).
Flamm, J. et al., Recurrent superficial transitional cell carcinoma of the bladder: Adjuvant topical chemotherapy vs. immunotherapy. A prospective randomized trial. J. Urol. 144:260-263 (1990).
Kalble, T. et al. Intravesikale rezidivprophylaze beim oberflachlichen harnblasenkarzinom mit BCG und KLH. Urologe 30:118-121 (1991).
Flamm, J. et al., Adjuvant topical chemotherapy versus immunotherapy in primary superficial transitional cell carcinoma of the bladder. Br. J. Urol. 67:70-73 (1991).
Lamm, D.L. et al., Immunotherapy of murine transitional cell carcinoma. J. Urol. 128:1104-1108 (1982).
Lamm, D.L. et al., Keyhole-limpet haemacyanin and immune ribonucleic acid immunotherapy of murine transitional cell carcinoma. Urol. Res. 9:227-230 (1981).
Lamm, D.L. et al., Immunotherapy of murine bladder cancer with keyhole limpet hemocyanin (KLH). J. Urol. 149:648-652 (1993).
Laemmli, U.K., Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227:680-685 (1970).
Van Holde, K.E. et al., Boundary analysis of sedimentation-velocity experiments with monodisperse and paucidisperse solutes. Biopolym. 17:1387-1403 (1978).
Vandenbark, A.A. et al., All KLH preparations are not created equal. Cell.Immunol. 60:240-243 (1981).
Chodak, G.W. and Summerhayes, I., Detection of angiogenesis activity in malignant bladder tissue and cells. J. Urol. 132:1032 (1984).
Shapiro, A., Ratliff, T.L., Oakley, D.M. and Catalona, W.J., Reduction of bladder tumor growth in mice treated with intravesical bacillus Calmette-Guerin and its correlation with bacillus Calmette-Guerin viability and natural killer cell activity. Cancer Res. 43:1611 (1983).
Wu, C.Y et al., Chemical Abstracts, 75:139026e (1971).
Chem. Abstr. 116:36518c.
Chem. Abstr. 101:68045c.
Computer Database Abstract of Micron-Microsc-ACTA 23:287-301 (1992).
Computer Database Abstract of Cell Tissue Res., 269:411-420 (1992).
Chem. Abstr. 95:199291k.
Derwent Abstract 89-179475/25 and Search Report of EP 320 528.
Chem. Abstr. 106:207290x.
Derwent Abstract 88-08767/02.
Computer Database Abstract of First Clinical Results in Urological Tumor Immunotherapy, pp. 159-282 (1987).
Computer Database Abstract of Lancet 1 (67814):1208-1212 (1973).
Ebert Ray F.
Swerdlow Richard D.
Blackstone William M.
PerImmune Holdings, Inc.
Sayala Chhaya D.
LandOfFree
Method using keyhole limpet hemocyanin composition with enhanced does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method using keyhole limpet hemocyanin composition with enhanced, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method using keyhole limpet hemocyanin composition with enhanced will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-859896